Synaptogenix (TAOX) Competitors $6.41 -0.68 (-9.59%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsSEC FilingsShort InterestTrendsBuy This Stock TAOX vs. SLGL, PMVP, CRVO, STRO, ABVC, RPTX, ARTV, VTVT, UNCY, and BYSIShould you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include Sol-Gel Technologies (SLGL), PMV Pharmaceuticals (PMVP), CervoMed (CRVO), Sutro Biopharma (STRO), ABVC BioPharma (ABVC), Repare Therapeutics (RPTX), Artiva Biotherapeutics (ARTV), vTv Therapeutics (VTVT), Unicycive Therapeutics (UNCY), and BeyondSpring (BYSI). These companies are all part of the "pharmaceutical products" industry. Synaptogenix vs. Its Competitors Sol-Gel Technologies PMV Pharmaceuticals CervoMed Sutro Biopharma ABVC BioPharma Repare Therapeutics Artiva Biotherapeutics vTv Therapeutics Unicycive Therapeutics BeyondSpring Synaptogenix (NASDAQ:TAOX) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends. Which has more risk & volatility, TAOX or SLGL? Synaptogenix has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Which has preferable earnings and valuation, TAOX or SLGL? Sol-Gel Technologies has higher revenue and earnings than Synaptogenix. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynaptogenix$3.96K5,641.51-$12.77M-$20.16-0.32Sol-Gel Technologies$11.54M8.41-$10.58M-$1.23-28.29 Does the media favor TAOX or SLGL? In the previous week, Synaptogenix's average media sentiment score of 0.00 equaled Sol-Gel Technologies'average media sentiment score. Company Overall Sentiment Synaptogenix Neutral Sol-Gel Technologies Neutral Do analysts recommend TAOX or SLGL? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Sol-Gel Technologies 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is TAOX or SLGL more profitable? Synaptogenix has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -14.25%. Sol-Gel Technologies' return on equity of -11.80% beat Synaptogenix's return on equity.Company Net Margins Return on Equity Return on Assets SynaptogenixN/A -277.76% -150.79% Sol-Gel Technologies -14.25%-11.80%-9.39% Do insiders and institutionals have more ownership in TAOX or SLGL? 10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummarySol-Gel Technologies beats Synaptogenix on 8 of the 12 factors compared between the two stocks. Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for TAOX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TAOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TAOX vs. The Competition Export to ExcelMetricSynaptogenixPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$22.35M$985.07M$2.50B$10.52BDividend YieldN/A4.84%2.50%4.68%P/E Ratio-0.321.2526.7426.67Price / Sales5,641.51126.13229.14204.76Price / CashN/A17.6446.1561.26Price / Book1.486.8037.946.55Net Income-$12.77M-$6.11M$12.55M$277.34M7 Day Performance9.57%1.32%1.78%2.41%1 Month Performance6.83%2.77%4.20%9.26%1 Year PerformanceN/A46.13%62.51%32.66% Synaptogenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TAOXSynaptogenix0.0541 of 5 stars$6.41-9.6%N/AN/A$22.35M$3.96K-0.324SLGLSol-Gel Technologies0.3346 of 5 stars$28.99+3.6%N/A+367.7%$80.76M$23.93M-23.5750Gap UpPMVPPMV Pharmaceuticals3.0323 of 5 stars$1.48+5.7%$5.50+271.6%-7.4%$78.43MN/A-0.9450CRVOCervoMed3.6292 of 5 stars$8.28+5.9%$19.29+132.9%-40.3%$76.61M$9.74M-3.174Positive NewsShort Interest ↓STROSutro Biopharma4.2777 of 5 stars$0.89+2.3%$4.47+403.8%-74.3%$75.16M$104.47M-0.35240Gap DownABVCABVC BioPharma0.777 of 5 stars$3.16+1.3%N/A+399.1%$74.39M$391.24K-18.5930RPTXRepare Therapeutics2.2778 of 5 stars$1.69+1.2%$4.50+166.3%-46.7%$72.60M$250K-0.66180ARTVArtiva Biotherapeutics3.3262 of 5 stars$2.96-1.7%$17.00+474.3%-81.2%$72.30MN/A0.0081Positive NewsVTVTvTv Therapeutics1.464 of 5 stars$22.48-1.5%$35.50+58.0%+67.0%$71.34M$17K-7.209Gap UpUNCYUnicycive Therapeutics2.5794 of 5 stars$4.02+7.5%$57.00+1,317.9%+21.2%$71M$680K-0.989BYSIBeyondSpringN/A$1.76+4.8%N/A-32.3%$70.98MN/A0.0080 Related Companies and Tools Related Companies Sol-Gel Technologies Alternatives PMV Pharmaceuticals Alternatives CervoMed Alternatives Sutro Biopharma Alternatives ABVC BioPharma Alternatives Repare Therapeutics Alternatives Artiva Biotherapeutics Alternatives vTv Therapeutics Alternatives Unicycive Therapeutics Alternatives BeyondSpring Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TAOX) was last updated on 10/3/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synaptogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TAOX Stock Alerts